These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37188765)

  • 1. Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Jeon JY; Yoo HJ; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Sung YK
    Sci Rep; 2023 May; 13(1):7877. PubMed ID: 37188765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
    Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
    Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
    Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
    Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
    Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a
    Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study.
    Shin A; Lee JH; Ha YJ; Lee YJ; Lee EB; Kang EH
    Semin Arthritis Rheum; 2022 Aug; 55():152019. PubMed ID: 35567808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
    Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
    Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
    Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
    Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan.
    Chen YJ; Chen YM; Huang WN; Chen HH; Liao TL; Chen JP; Hsieh TY; Chen YH; Chen DY
    Medicine (Baltimore); 2020 Oct; 99(41):e22504. PubMed ID: 33031288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
    Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
    Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study.
    Harada S; Sakai R; Hirano F; Miyasaka N; Harigai M;
    J Rheumatol; 2017 Jul; 44(7):988-995. PubMed ID: 28412701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
    Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
    Bing N; Zhou H; Chen X; Hirose T; Kochi Y; Tsuchida Y; Ishigaki K; Sumitomo S; Fujio K; Zhang B; Valdez H; Vincent MS; Martin D; Clark JD
    Arthritis Rheumatol; 2021 Jul; 73(7):1155-1166. PubMed ID: 33455090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea.
    Kim YE; Kim YJ; Jeong DH; Kim S; Kim MJ; Kim HH; Jo KW; Park SH; Hong S
    Semin Arthritis Rheum; 2024 Apr; 65():152362. PubMed ID: 38281468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
    Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
    Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.